Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT03933384
PHASE4
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Sponsor: Taichung Veterans General Hospital
View on ClinicalTrials.gov
Summary
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Official title: Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2019-08-19
Completion Date
2030-12-31
Last Updated
2025-01-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tenofovir alafenamide
Tenofovir alafenamide 25mg/tab once daily
DRUG
Entecavir
Entecavir 0.5mg/tab once daily
Locations (1)
Taichung Veterans General Hospital
Taichung, Taichung, Taiwan